AveXis
Latest round
- Series D
Last raised
- Sep 2015
Total raised
- $75M
Investors
- 12
About AveXis
AveXis, Inc.Founded in 2010 in Bannockburn, US, AveXis specializes in gene therapy solutions for spinal muscular atrophy and other conditions.7 bn.AveXis develops gene therapies targeting severe neurological disorders, including its flagship product Zolgensma®, designed for spinal muscular atrophy.AveXis plans to expand its product portfolio with upcoming gene therapies targeting additional rare diseases. The company intends to penetrate new markets in Europe and Asia by 2020. The recent acquisition by Novartis will enhance its capabilities to fund these initiatives, ensuring broader access to its innovative therapies.
Who invested in AveXis
12 investors across 2 rounds
See all investors in AveXis
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about AveXis
Who invested in AveXis?
AveXis has 12 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has AveXis raised?
AveXis has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did AveXis last raise money?
AveXis's most recent round on record is a Series D, in Sep 2015.
What does AveXis do?
AveXis is a biotechnology company.
Where is AveXis headquartered?
AveXis is headquartered in Bannockburn, US.
Which VCs invest in companies like AveXis?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at AveXis's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like AveXis? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.